- Home
- MAN vs ADPT Comparison
MAN vs ADPT Comparison
Compare MAN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAN
- ADPT
- Stock Information
- Founded
- MAN 1948
- ADPT 2009
- Country
- MAN United States
- ADPT United States
- Employees
- MAN N/A
- ADPT N/A
- Industry
- MAN Professional Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAN Consumer Discretionary
- ADPT Health Care
- Exchange
- MAN Nasdaq
- ADPT Nasdaq
- Market Cap
- MAN 1.8B
- ADPT 2.0B
- IPO Year
- MAN 1988
- ADPT 2019
- Fundamental
- Price
- MAN $33.22
- ADPT $17.32
- Analyst Decision
- MAN Hold
- ADPT Strong Buy
- Analyst Count
- MAN 6
- ADPT 10
- Target Price
- MAN $41.33
- ADPT $15.10
- AVG Volume (30 Days)
- MAN 1.0M
- ADPT 2.0M
- Earning Date
- MAN 10-16-2025
- ADPT 11-05-2025
- Dividend Yield
- MAN 6.83%
- ADPT N/A
- EPS Growth
- MAN N/A
- ADPT N/A
- EPS
- MAN N/A
- ADPT N/A
- Revenue
- MAN $17,643,700,000.00
- ADPT $205,216,000.00
- Revenue This Year
- MAN $0.74
- ADPT $34.41
- Revenue Next Year
- MAN $3.40
- ADPT $14.03
- P/E Ratio
- MAN N/A
- ADPT N/A
- Revenue Growth
- MAN N/A
- ADPT 21.60
- 52 Week Low
- MAN $32.86
- ADPT $4.27
- 52 Week High
- MAN $66.50
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- MAN 29.81
- ADPT 64.30
- Support Level
- MAN $32.86
- ADPT $16.21
- Resistance Level
- MAN $34.87
- ADPT $17.89
- Average True Range (ATR)
- MAN 1.57
- ADPT 0.81
- MACD
- MAN -0.42
- ADPT 0.08
- Stochastic Oscillator
- MAN 4.96
- ADPT 85.81
About MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).